Listed

Immunovant, Inc.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 10, 2023 and accepted by EDGAR at Aug 10, 2023, 07:19 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Income tax3 months2023-04-01 to 2023-06-30−$11.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30−$73.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$0.57us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$0.57us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-30130,503,264 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-04-01 to 2023-06-30−$47.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-04-01 to 2023-06-30$45.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-06-30$330.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$350.0mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$351.2mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$51.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$51.4mus-gaap:Liabilities
Shareholders' equityAt period end2023-06-30$299.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001764013-23-000092. Last ingested by Listed: Nov 13, 2026, 16:26 ET. Listed shows no prices and gives no investment advice.